QR код

Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO)

Abstract Background The identification of homologous recombination deficient (HRD) tumor is now a crucial step for the therapeutic management of ovarian cancer. The HRD tumors are both sensitive to olaparib maintenance treatment and to platinum-based chemotherapy. Despite the large amount of HRD tes...

Повний опис

Збережено в:
Автори: Raphaël Leman, François Cherifi, Marianne Leheurteur, Pierrick Theret, Camille Pasquesoone, Mathilde Saint-Ghislain, Lucie Bresson, Christophe Denoyelle, Nicolas Vigneron, Laurent Poulain, Raphaël Delepee, Benoit Berby, Julie Dremaux, Aurélie Dumont, Cécile Blanc-Fournier, Corinne Jeanne, Mélanie Briand, Nathalie Rousseau, Louis-Ferdinand Pepin, Elodie Deruche, Fabienne Dumont, Alexandra Leconte, Justine Lequesne, Bénédicte Clarisse, Florence Joly, Laurent Castera, Roman Rouzier
Формат: Artigo
Мова:Inglês
Опубліковано: BMC 2025-07-01
Серія:BMC Cancer
Предмети:
Molecular biology
Ovarian cancer
Homologous recombination deficiency
Platinum resistance
Онлайн доступ:https://doi.org/10.1186/s12885-025-14423-2
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси